Genomic landscape of high-grade meningiomas

Brain tumors: uncovering genomic disruption in meningiomas Meningiomas, which arise from the tissue surrounding the brain and spinal cord, are the most common primary brain tumor in adults. The majority of these are slow-growing and amenable to surgical resection, if treatment is indicated. However,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wenya Linda Bi, Noah F. Greenwald, Malak Abedalthagafi, Jeremiah Wala, Will J. Gibson, Pankaj K. Agarwalla, Peleg Horowitz, Steven E. Schumacher, Ekaterina Esaulova, Yu Mei, Aaron Chevalier, Matthew A. Ducar, Aaron R. Thorner, Paul van Hummelen, Anat O. Stemmer-Rachamimov, Maksym Artyomov, Ossama Al-Mefty, Gavin P. Dunn, Sandro Santagata, Ian F. Dunn, Rameen Beroukhim
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
R
Acceso en línea:https://doaj.org/article/30b733f570624d2fb8c0cba27d4db819
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Brain tumors: uncovering genomic disruption in meningiomas Meningiomas, which arise from the tissue surrounding the brain and spinal cord, are the most common primary brain tumor in adults. The majority of these are slow-growing and amenable to surgical resection, if treatment is indicated. However, a subset of aggressive meningiomas are considered high-grade, producing significantly worse mortality. In a first study of its kind, Drs. Wenya Linda Bi, Ian Dunn, Sandro Santagata, Rameen Beroukhim, and colleagues at Harvard Medical School sequenced the genomes of 134 high-grade meningiomas and compared their makeup with lower-grade meningiomas. They found that aggressive tumors were more likely to harbor mutations in the NF2 gene and exhibit widespread genomic disruption. They also harbored an elevated rate of predicted immunogenic mutations, with implications for the use of immuno-modulatory therapies.